Larimar Pharma (LRMR) - שולי הרווח הגולמי

LRMR (Larimar Therapeutics Inc) - סמל מסחרי של החברה

Historical gross margin demonstrates the efficiency of Larimar Therapeutics (LRMR), where the 0.00 mark indicates the profitability level. Patent protection and orphan drug status ensure the company's long-term dominance. However, a high pipeline concentration on a single primary candidate creates significant binary risks. At the same time, colossal R&D investments establish a powerful foundation for developing breakthrough therapies for Friedreich's ataxia.

LRMR: שולי רווח גולמי Larimar Therapeutics 04.07.2022 - 20.11.2026

פילוחי מדדים פיננסיים ומדדי שוק עבור larimartx.com (LRMR)

- מחיר שוק ויעדי מחיר של אנליסטים:
ניתוח בסיסי של החברה:LRMR, Larimar Therapeutics, Inc.
מוצרים מיוצרים של Larimar Therapeutics

Assessing the reliability of equity assets begins with analyzing a business's ability to generate profit over direct costs. Gross margin measures the portion of revenue minus the cost of goods sold, which for the biotech firm Larimar Therapeutics (LRMR), facing binary risks associated with a single drug, is critical for controlling operational efficiency; therefore, any increase in gross margin signals a reduction in production costs amid clinical trials.